Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

On each of two treatment days, subjects will consume a standard high fat meal and then
receive either (A) a single inhaled dose of CVT-301 or (B) a single dose of oral CD/LD
followed by Pharmacokinetic (PK) sampling for 4 hours. A crossover design will be used such
that each subject receives both Treatment A and Treatment B over the 2 treatment days,
randomized 1:1 to the treatment sequence AB or BA.

Inclusion Criteria:

- Men and women between the ages of 30 and 85 years, inclusive.

- Have idiopathic PD (i.e., not induced by drugs or other diseases) as defined by
fulfilling Steps 1 and 2 of the United Kingdom (UK) Brain Bank criteria, diagnosed
after the age of 30 years.

- Classified as Stage 1 to 3 (in the ON state) on the modified Hoehn and Yahr scale for
staging of PD severity.

- Stable on other non levodopa PD medications for at least 4 weeks prior to the
Screening Visit.

- Subjects must have normal cognition as confirmed by a score of ≥ 25 on the Mini Mental
State Examination (MMSE), performed in the ON state.

- Forced expiratory volume in one second (FEV1) ≥60% of predicted for race, age, sex,
and height and FEV1/FVC (forced vital capacity) ratio ≥70%.

- Body Mass Index (BMI) between 18 - 32 kg/m2, inclusive.

Exclusion Criteria:

- Any flu-like syndrome or other respiratory infections within 2 weeks prior to the
Screening Visit.

- Chronic obstructive pulmonary disease (COPD), asthma, or other chronic respiratory
disease within the last 5 years.

- History of any cancer in the past 5 years with the exception of successfully treated
basal cell carcinoma.

- Narrow angle glaucoma or a history of peptic ulcer disease less than 1 year prior to
screening.

- Previous surgery for PD (including but not limited to deep brain stimulation or cell
transplantation).

- Current use of nicotine patch or tobacco-containing products including cigarettes,
electronic cigarettes, cigars, chewing tobacco, pipe tobacco or snuff or use within 4
weeks prior to the Screening Visit, or expected use during the study.

- Marijuana smoking within 4 weeks prior to the Screening Visit, or expected
smoking/inhalation during the study.